Cassava pays $40M over allegedly misleading Alzheimer's update
WEB1 day ago · Cassava’s presentation of the data showed a -1.5 change on placebo and up to -5.7 on simufilam. Burns is paying $85,000 to settle her part of the case. Burns is paying $85,000 to settle her part ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB2 days ago · September 26, 2024 at 7:11PM EDT. (Bloomberg) -- Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial. Cassava published results in …
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC ...
WEB1 day ago · Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated ...
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial …
WEB1 day ago · Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...
Cassava Agrees to Pay $40M Fine to Resolve SEC Probe as
WEB1 day ago · Cassava Sciences on Thursday announced that it reached a settlement with the Securities and Exchange Commission over an investigation into allegations of data manipulation involving the company’s Alzheimer’s drug candidate simufilam.. The biotech agreed to pay a $40 million civil penalty to settle the probe, while maintaining that the settlement comes “without admitting or denying the ...
Cassava Sciences Resolves SEC Investigation - Yahoo Finance
WEB2 days ago · Advertisement. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s ...
Cassava Sciences and former execs agree to SEC fines | STAT
WEB2 days ago · Cassava was charged Thursday by the SEC with making misleading claims in 2020 about trials for its Alzheimer's drug, and agreed to pay fines. ... The news comes on the same day that the SEC filed ...
US charges Cassava Sciences, two former executives for ... - Yahoo
WEB2 days ago · WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
WEBJul 18, 2024 · Two top officials at Cassava Sciences — a small pharmaceutical company in Austin, Texas, embroiled in years of controversy over a proposed Alzheimer’s drug — have resigned.
Cassava Sciences Reports Q1 2024 Financial Results and Clinical …
WEBMar 31, 2024 · Financial Results for First Quarter 2024. At March 31, 2024, cash and cash equivalents were $124.2 million, with no debt. The total gross proceeds received from the cash-exercise of Warrants were $126.3 million, including approximately $104.0 million received in April and May 2024.
- Some results have been removed
Skip to content